What is Cogent Biosciences, Inc.'s debt repayments?

Cogent Biosciences, Inc. (COGT) reported debt repayments of $13.66M in Q4 2025.

What does debt repayments mean?

Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.

Cogent Biosciences, Inc. COGT Debt Repayments

Debt Repayments at other companies

AmgenAMGN

$833M-66.7%

Scholar RockSRRK

$103.06M+304%

Other financials

Income statement

See full

Operating income-$103.6M-38.3%

Net income-$97.4M-35.2%

EPS (diluted)-$0.53-1.9%

Balance sheet

See full

Cash & equivalents$241.2M+91.4%

Total debt$15.5M-9.4%

Total equity$607.7M+177%

Total assets$903.0M+218%

Cash flow

See full

Operating cash flow-$86.9M-30.6%

CapEx$449.0K-17.9%

Free cash flow-$87.3M-30.2%

Valuation

See full

Market cap$5.9B+816%

Profitability

See full

Operating margin-1,044.3%—

Net margin-950.4%—

FCF margin-184.7%—

Returns & leverage

See full

Return on equity-85.7%+1.7pp

Debt / equity0×-0.1×

Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfDebt.

The official record: Cogent Biosciences, Inc.’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s debt repayments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s debt repayments?: Cogent Biosciences, Inc. (COGT) reported debt repayments of $13.66M in Q4 2025.
What does debt repayments mean?: Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.